292 related articles for article (PubMed ID: 33774187)
21. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
22. Immune-related cutaneous adverse events: A new opportunity for allergists and clinical immunologists.
Leung DYM
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):607. PubMed ID: 34049668
[No Abstract] [Full Text] [Related]
23. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
[No Abstract] [Full Text] [Related]
24. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
25. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
Raibagkar P
Immunol Lett; 2020 May; 221():72-74. PubMed ID: 32092358
[No Abstract] [Full Text] [Related]
27. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
28. Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial.
Cabarrou B; Gomez-Roca C; Viala M; Rabeau A; Paulon R; Loirat D; Munsch N; Delord JP; Filleron T
Invest New Drugs; 2020 Dec; 38(6):1879-1887. PubMed ID: 32383099
[TBL] [Abstract][Full Text] [Related]
29. Rare, but Severe: Vasculitis and Checkpoint Inhibitors.
Lindner AK; Gruenbacher G; Schachtner G; Thurnher M; Pichler R
Eur Urol Focus; 2020 May; 6(3):609-612. PubMed ID: 31072806
[TBL] [Abstract][Full Text] [Related]
30. Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
Ribero S; Quaglino P; Roccuzzo G
Br J Dermatol; 2024 Jun; 191(1):12. PubMed ID: 38419417
[No Abstract] [Full Text] [Related]
31. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
Okiyama N; Tanaka R
Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
Kumar P; Saini S; Prabhakar BS
Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
[TBL] [Abstract][Full Text] [Related]
33. Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
Gomes-Lima CJ; Zhou W; Quandt Z
Front Endocrinol (Lausanne); 2023; 14():1268402. PubMed ID: 37766679
[No Abstract] [Full Text] [Related]
34. Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists.
Kim ST; Suarez-Almazor ME
Expert Rev Clin Immunol; 2019 Mar; 15(3):211-213. PubMed ID: 30589372
[No Abstract] [Full Text] [Related]
35. Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?
Percik R; Shoenfeld Y
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101411. PubMed ID: 32278687
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
[TBL] [Abstract][Full Text] [Related]
37. How to select cancer patients for immunotherapy.
Pfeiffer P; Qvortrup C; Hansen KH
EBioMedicine; 2021 Jan; 63():103184. PubMed ID: 33418504
[No Abstract] [Full Text] [Related]
38. Immune checkpoint inhibitors: a promising anticancer therapy.
Singh S; Hassan D; Aldawsari HM; Molugulu N; Shukla R; Kesharwani P
Drug Discov Today; 2020 Jan; 25(1):223-229. PubMed ID: 31738877
[TBL] [Abstract][Full Text] [Related]
39. Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors.
Inaba H; Ariyasu H; Iwakura H; Kurimoto C; Takeshima K; Morita S; Furuta H; Hotomi M; Akamizu T
Endocr J; 2021 Feb; 68(2):231-241. PubMed ID: 33012745
[TBL] [Abstract][Full Text] [Related]
40. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
Yao S; Li X; Nong J; Zhang Y
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]